Mankind Pharma joins hands with Daewoong Pharma for clinical trial of Covid drug Niclosamide

"We are excited to collaborate with Daewoong Pharmaceutical Co Ltd to bring novel formulation of Niclosamide(DWRX2003) for the treatment of Covid-19 patients in India.

Published On 2020-08-13 06:31 GMT   |   Update On 2021-08-12 08:34 GMT
Advertisement

New Delhi: Mankind Pharma on Tuesday said it has collaborated with South Korean firm Daewoong Pharmaceutical Co for conducting phase-I clinical trial of a novel formulation of Niclosamide for the treatment of Covid-19 patients in India.

The trial is designed towards addressing the need for an investigation on this new formulation based on encouraging preclinical evidence for the treatment of Covid-19, Mankind Pharma said in a statement.

Advertisement

"We are excited to collaborate with Daewoong Pharmaceutical Co Ltd to bring novel formulation of Niclosamide (DWRX2003) for the treatment of Covid-19 patients in India.

"We believe that the product would provide for a safe and effective alternative to patients suffering from this disease," Mankind Pharma COO Arjun Juneja said.

Both companies have received approval from the Drugs Controller General of India (DCGI) to conduct phase-1 clinical trials.

Daewoong Pharmaceutical CEO Sengho Jeon said, "Through the development of candidates for Covid-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide innovative treatment option for patients suffering from Covid-19."

Mankind Pharma is one of the best partners to accelerate the clinical development and supply of DWRX2003 for India, he added.

Read also: Mankind Pharma To Give Rs 5 Crore To Families Of Deceased COVID Warriors

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News